WeTrials
Recruiting

DCIS: RECAST Trial -Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: a Breast Cancer Prevention Pilot Study

What is this study?

This study is testing whether closely monitoring early-stage breast cancer, called ductal carcinoma in situ, using hormone therapy instead of immediate surgery is safe and effective. It aims to help patients avoid invasive surgeries when careful observation and medication can manage the condition well.

Who can participate?

Adult women who have been diagnosed with a specific early-stage, hormone-positive breast cancer and have specific margins from previous tissue removal. Participants must be willing to temporarily stop any current hormone-blocking therapies and cannot be pregnant or breastfeeding.

What will happen?

Participants will take a prescribed hormone therapy medicine and return for breast MRI scans at three and six months to check on the cancer. You will also be asked to provide blood and saliva samples, and allow researchers to use a portion of existing tissue samples for testing.

Where and when?

This study is currently recruiting participants and takes place at multiple locations in California, United States.

Key Points
  • 1Exploring active monitoring and medication instead of immediate surgery for early breast cancer.
  • 2Involves taking hormone therapy and getting regular MRI scans at 3 and 6 months.
  • 3Currently recruiting participants at study sites in California.

Related video

CBS News Bay Area: UCSF's RECAST trial tests hormone therapy and monitoring for DCIS (October 2025)

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Ductal Carcinoma in Situ

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.